- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 90,510 | 05.06.24 17:35:52 | -0,020 | -0,02% | 0,000 | 0,000 | 90,920 | 90,530 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.007,220 | 05.06.24 21:53:33 | +13,930 | +1,40% | 1.006,560 | 1.008,080 | 989,790 | 993,290 |
